[114977-28-5] Docetaxel AKSci J10086
 
 
Loading Please Wait...
  J10086    
Docetaxel
, 99% (HPLC)
 
Taxotere
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol




IDENTITY
CAS Number:[114977-28-5]
MDL Number:MFCD00800737
MF:C43H53NO14
MW:807.88
SPECIFICATIONS & PROPERTIES
Purity:99% (HPLC)
Available Spectra:FT-IR, LCMS, HPLC, Polarimetry
Physical Form:White to off-white powder
Melting Point:186-192°C
Optical Rotation:-32° to -43° (c=0.74, EtOH)
Long-Term Storage:Store at room temperature

BIOLOGICAL INFO
Solubility:DMSO: 162mg/mL; H2O: <1mg/mL; EtOH: 162mg/mL
Application(s):Microtubule disassembly inhibitor
Form:Free Base

REVIEW

 Docetaxel interferes with the normal function of microtubule growth. Whereas drugs like colchicine cause the depolymerization of microtubules in vivo, docetaxel arrests their function by having the opposite effect; it hyper-stabilizes their structure. This destroys the cell's ability to use its cytoskeleton in a flexible manner. Specifically, docetaxel binds to the β-subunit of tubulin. Tubulin is the "building block" of mictotubules, and the binding of docetaxel locks these building blocks in place. The resulting microtubule/docetaxel complex does not have the ability to disassemble. This adversely affects cell function because the shortening and lengthening of microtubules (termed dynamic instability) is necessary for their function as a transportation highway for the cell. Chromosomes, for example, rely upon this property of microtubules during mitosis. Further research has indicated that docetaxel induces programmed cell death (apoptosis) in cancer cells by binding to an apoptosis stopping protein called Bcl-2 (B-cell leukemia 2) and thus arresting its function

REFERENCES
[1]Lyseng-Williamson KA, Fenton C (2005). ''''Docetaxel: a review of its use in metastatic breast cancer. Drugs 65 (17): 2513-31. PMID 16296875
[2] Clarke SJ, Rivory LP (February 1999). ''''Clinical pharmacokinetics of docetaxel''''. Clin Pharmacokinet 36 (2): 99-114. doi:10.2165/00003088-199936020-00002. PMID 10092957.
[3] A. Michael,K.Syrigos,H.Pandha (2009). Prostate cancer chemotherapy in the era of targeted therapy. Prostate Cancer and Prostatic Diseases 12 (1): 13-16. doi:10.1038/pcan.2008.32. PMID 18521103.
[4] Anonymous. Oncology Tools: Approved Claims for microtubule inhibitors. US Food and Drug Administration. at web.archive.org (17 Sep 2006). Last modified 22 Jun 1998.

GHS

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501


Current as of June 25, 2017


Download SDS

CATEGORIES

 APIs and Bioactives > Alkaloids, Chemotherapeutics


PubChem